Pooled analysis of long-term survival data from phase II and phase III trials of ipilimumab in unresectable or metastatic melanoma Review uri icon

Overview

MeSH Major

  • Antibodies, Monoclonal
  • Antineoplastic Agents
  • Melanoma
  • Skin Neoplasms

abstract

  • To our knowledge, this is the largest analysis of OS to date for ipilimumab-treated patients with advanced melanoma. We observed a plateau in the survival curve, beginning at approximately 3 years, which was independent of prior therapy or ipilimumab dose. These data add to the evidence supporting the durability of long-term survival in ipilimumab-treated patients with advanced melanoma.

publication date

  • June 10, 2015

Research

keywords

  • Review

Identity

Language

  • eng

PubMed Central ID

  • PMC5089162

Digital Object Identifier (DOI)

  • 10.1200/JCO.2014.56.2736

PubMed ID

  • 25667295

Additional Document Info

start page

  • 1889

end page

  • 94

volume

  • 33

number

  • 17